Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytoSorbents' SEC filings reveal the financial dynamics of a biotech company balancing commercial operations in international markets with ongoing U.S. regulatory pursuits. Unlike large pharmaceutical companies with diversified revenue streams, CTSO's filings show concentrated dependence on CytoSorb cartridge sales—making quarterly revenue trends particularly meaningful for assessing commercial traction.
The company's 10-K annual reports detail research and development expenditures for products like DrugSorb-ATR alongside sales and marketing investments supporting international expansion. These filings break down revenue by geography, showing performance across European markets where CytoSorb holds regulatory approval versus regions served through distributor partnerships. Cash burn rates and runway calculations matter significantly for a company at CytoSorbents' stage.
10-Q quarterly filings provide interim snapshots of cartridge sales momentum and operating expenses. For biotech investors, these reports offer leading indicators of whether commercial adoption accelerates or plateaus between annual reports. Our AI summaries highlight quarter-over-quarter revenue changes and notable expense shifts without requiring you to parse accounting footnotes.
8-K filings from CytoSorbents often carry regulatory significance—FDA correspondence, clinical milestone announcements, and material business developments appear here. Given the company's active pursuit of U.S. market approval, these current reports frequently contain developments that move the stock.
Form 4 insider transactions track executive and director stock activity. In smaller biotech companies, insider buying or selling patterns sometimes precede significant announcements. Our platform aggregates these transactions for quick pattern recognition across CytoSorbents' management team.
Cytosorbents Corp (CTSO) reported that its Chief Executive Officer and director, Phillip P. Chan, acquired additional company stock in an open market transaction. On 11/18/2025, he purchased 100,000 shares of Common Stock at a price of $0.64 per share. Following this transaction, he beneficially owns 1,482,963 shares, reflecting both directly owned shares and various restricted stock units (RSUs).
The footnotes explain that his holdings include multiple RSU grants that either vest upon a "Change In Control" under the company’s 2014 Long-Term Incentive Plan or in equal parts on the first and second anniversaries of their grant dates, subject to continued service. His position also includes 1,113,363 shares of Common Stock owned outright.
CytoSorbents Corporation announced that it issued a press release with financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 under Item 2.02.
The company states this information is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except as specifically stated.
Cytosorbents Corp. (CTSO) filed a Form 144 reporting a proposed sale of 10,548 common shares through Fidelity Brokerage Services with an approximate sale date of 08/19/2025. The filing shows the shares were acquired on 08/14/2025 by restricted stock vesting from the issuer as compensation. The aggregate market value of the planned sale is listed as $11,447.74 and the company reports 62,761,805 shares outstanding. No other sales in the past three months are reported.
Phillip P. Chan, Chief Executive Officer and director of Cytosorbents Corp (CTSO), reported equity awards and holdings on 08/08/2025. The filing shows an acquisition of 105,600 restricted stock units (RSUs) with a reported price of $0 and a grant of 136,400 stock options with a $1 exercise price and an expiration date of 08/08/2035. Following the reported transactions, the filing reports 1,382,963 shares of common stock beneficially owned. Footnotes disclose multiple prior RSU grants (2015–2024), including 48,000 unvested RSUs from April 2, 2024, and state that 1,013,363 shares are owned outright by the reporting person. The RSUs and options vest in scheduled tranches and vesting generally requires continued service.
CytoSorbents director Edward R. Jones reported a change in beneficial ownership showing a disposition of 88,834 shares of Common Stock on 08/08/2025. The filing states that the 88,834 shares comprise 69,300 Restricted Stock Units (grants from 2015, 2016, 2017 and 2018 that vest on a defined "Change In Control") and 19,534 shares owned outright by the reporting person. The filing also shows an acquisition of 22,000 stock options granted under the company plan with a $1 exercise price; those options vest in four equal quarterly installments over one year following grant and appear to expire on 08/08/2035. The Form 4 was submitted as a single reporting person filing and includes a Power of Attorney exhibit.
Michael G. Bator, a director of Cytosorbents Corporation (CTSO), reported a transaction dated 08/08/2025 in which he disposed of 151,273 shares of common stock and was granted stock options to purchase 44,000 shares at an exercise price of $1. The 151,273 shares reported include 3,300 RSUs (granted 03/15/2018), 6,000 RSUs (02/24/2017), 60,000 RSUs (06/07/2016) that vest upon a Change of Control, and 81,973 shares owned outright by the reporting person. The options were granted under the CytoSorbents 2014 Long-Term Incentive Plan and vest in four equal quarterly installments over one year, subject to continued service, with an expiration indicated as 08/08/2035.
Peter J. Mariani, Chief Financial Officer of Cytosorbents Corp. (CTSO), reported insider awards and holdings dated 08/08/2025. The filing shows an acquisition of 71,500 shares of Common Stock represented by restricted stock units (RSUs) at a reported price of $0. The report also discloses a grant of 90,000 stock options with an exercise/conversion price of $1 and an expiration reference of 08/08/2035. Option vesting is described in the filing.
The filing lists total common stock beneficially owned following the reported transaction as 538,113 shares and details additional RSU awards: 110,000, 65,000, and 175,000 subject to various vesting conditions, plus 116,613 shares owned by the reporting person. Vesting schedules for the RSUs and the options are specified in the footnotes.
Insider reported: Director Jiny Kim disclosed changes in beneficial ownership of Cytosorbents Corporation (CTSO). The Form 4 shows a reported disposition of 77,819 shares of Common Stock and an acquisition of 22,000 stock options with a $1 exercise price. The options were granted under the companys long-term incentive plan and will vest in four equal quarterly installments over one year following the grant, subject to continued service.
The 77,819 figure includes 69,300 RSUs that convert to shares only upon a defined change in control and 8,519 shares directly owned by the reporting person. The filing was signed by an attorney-in-fact and references a power of attorney exhibit.
FAQ
What is the current stock price of Cytosorbents (CTSO)?
What is the market cap of Cytosorbents (CTSO)?
